Clinical trial NCT02029729: RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
Official title: An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic or Incurable Non-small Cell Lung Cancer
Relapsed, Refractory Melanoma
Keywords: RTA 408
RTA 408 Capsules
Non-small cell lung cancer
Metastatic non-small cell lung cancer
Incurable non-small cell lung cancer
Refractory melanoma
Relapsed melanoma
Lead sponsor: Biogen
Sponsor class: INDUSTRY
Collaborators: name: AbbVie
First posted: 2014-01-08
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are refractory after standard of care therapy for the disease. The results of this study will help provide clinical information for the design and conduct of further clinical studies with RTA 408 in cancer patients.


Eligibility criteria: Inclusion Criteria:

1. Adult male and female patients (18 to 75 years of age, inclusive);
2. Histologically or cytologically documented advanced NSCLC who have Stage IIIB/Stage IV disease, or recurrent disease following radiation therapy or surgical resection or advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma;
3. Patients must have experienced disease recurrence or progression during or after prior treatment with one or more prior standard systemic therapies;
4. Patients with epidermal growth factor receptor (EGFR) overactivity mutations or anaplastic lymphoma kinase (ALK) rearrangements must have received tyrosine-kinase inhibitor (TKI) therapy prior to consideration for enrollment;
5. Life expectancy \> 3 months;
6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
7. Have discontinued previous treatments for cancer and recovered from all acute toxic effects of prior systemic therapy (except alopecia) to grade ≤1;
8. Have adequate bone marrow reserve and organ function at screening as follows:

   1. Hematologic: Absolute neutrophil count \> 1.5 x 109/L, platelets \> 100 x 109/L, hemoglobin ≥ 9 g/dL (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. The first dose of study drug must not begin until 5 days after the erythrocyte transfusion);
   2. Hepatic: total bilirubin ≤ 1.5 X ULN, ALT and AST ≤ ULN;
   3. Renal: estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease (MDRD) formula ≥ 50 mL/min;
9. Willing to practice methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) from screening through 3 months after taking the final dose of RTA 408;
10. Female patients of childbearing potential must be non-pregnant, non-lactating, and have a negative pregnancy test result prior to enrollment in the study;

Exclusion Criteria:

1. Concurrent active malignancy other than adequately treated nonmelanomatous cell skin cancers, superficial bladder cancer, or carcinoma in situ of the cervix or breast;
2. Patients who previously had brain metastases (screening not required) unless they have met all of the following criteria:

   1. Patient had a resection and/or completed a course of cranial irradiation; and
   2. Patient has no worsening central nervous system symptoms; and
   3. Patient has discontinued all corticosteroids for that indication for at least 2 weeks;
3. Cardiovascular abnormalities:

   1. Evidence of poor cardiovascular function defined as b-type natriuretic peptide (BNP) \> 100 pg/mL, or history of congestive heart failure, unstable angina, uncontrolled hypertension, or clinically significant ventricular arrhythmias at screening;
   2. Myocardial infarction within 6 months prior to screening;
   3. QTcF interval on electrocardiogram (ECG) at screening \> 450 msec for males or \> 460 for females;
4. Known hepatic impairment including cirrhosis, known renal impairment including renal insufficiency or glomerulonephritis and severe cerebral or peripheral vascular disease;
5. Any gastrointestinal disorder with diarrhea as a major symptom, such as Crohn's, or pre- existing chronic diarrhea CTCAE Grade ≥ 2 of any etiology. Included are malabsorption disorders or surgical procedures that in the opinion of the investigator may affect absorption of study drug;
6. Known active fungal, bacterial, and/or known viral infection including human immunodeficiency (HIV) or viral (A, B, or C) hepatitis (screening is not required).;
7. Major surgery within 21 days before Study Day 1;
8. Have taken any of the following drugs within 7 days prior to Study Day 1:

   1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide, midazolam, sildenafil);
   2. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin), OCT1 transporter (e.g., metformin), OAT1 transporter (e.g., captopril, furosemide, methotrexate), and OATP1B3 transporter (e.g., atorvastatin, rosuvastatin, valsartan);
9. Known or suspected active drug or alcohol abuse;

Primary outcomes:
measure: Dose Determination
timeFrame: 1 year (28-day cycles, up to 12 cycles per patient)
Secondary outcomes:
Other outcomes:
Locations:
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center (NSCLC)
state: Florida
Study officials:
References: